实用肝脏病杂志 ›› 2015, Vol. 18 ›› Issue (6): 638-642.doi: 10.3969/j.issn.1672-5069.2015.06.018

• 肝癌 • 上一篇    下一篇

影响乙型肝炎病毒相关原发性肝癌患者生存因素分析

季伟, 王炜, 吕金捍, 金立元, 郭英君, 丁荣华, 胡燕梅, 孙燕燕   

  1. 750001 银川市 宁夏回族自治区人民医院感染性疾病科(季伟,郭英君,丁荣华,胡燕梅,孙燕燕); 肝胆外科(王炜,吕金捍,金立元)
  • 收稿日期:2015-03-25 出版日期:2015-11-20 发布日期:2016-02-04
  • 作者简介:季伟,男,55岁, 医学博士,主任医师。主要从事肝脏疾病的诊疗工作。E-mail:great_jee_8@hotmail.com

Risk factors influencing survival of patients with hepatitis B virus-related primary liver cancer

Ji Wei, Wang Wei, Lyu Jinhan, et al.   

  1. Department of Infectious Diseases,People’s Hospital,Yinchuan 750001,Ningxia Hui Autonomous Region, China
  • Received:2015-03-25 Online:2015-11-20 Published:2016-02-04

摘要: 目的分析乙型肝炎病毒相关原发性肝癌(HBV-PLC)患者生存期及其影响因素。方法收集2011年11月至2014年6月我院119例HBV-PLC患者临床资料,应用Kaplan-Meier检验及Cox回归模型,分析影响HBV-PLC患者生存期的因素。结果在119例HBV-PLC患者中,终末期肝癌比例较高,BCLC D期患者41例(34.5%),Child-Pugh C级79例(66.4%),伴有基础疾病78例(65.5%),肿瘤肝内或肝外转移90例(75.6%),患者中位生存期为287(172,560) d;在HBV-PLC确诊前未抗病毒治疗、抗病毒治疗持续时间<1年、1~3年和>3年患者的中位生存期分别为232(114,390) d、357(179,879) d、530(206,-) d和795(384,912)d(P<0.01);Cox回归分析提示,民族、Child-Pugh分级、肿瘤转移、年龄、抗病毒治疗、血清HBV DNA水平和肿瘤治疗方式是预测患者生存期的重要因素,相对危险度分别为3.18、1.60、4.86、1.82、1.30、5.88和1.13(P<0.05或P<0.01)。结论影响HBV-PLC患者生存期的因素很多,早期监测、早期干预、规范抗肿瘤治疗将有助于延长HBV-PLC患者的生存期。

关键词: 原发性肝癌, 乙型肝炎, 危险因素, 生存期

Abstract: Objective To clarify the prognostic factors that influence the overall survival(OS)in patients with hepatitis B virus-related primary liver carcer(HBV-PLC). Methods The clinical data of 119 patients with HBV-PLC from November 2011 to June 2014 in our hospital were retrospectively reviewed,and OS was analyzed by using Kaplan-Meier method,Log-rank test and Cox proportional hazard model. Results There were 41 cases (34.5%) with terminal stage of tumor [Barcelona Clinic Liver Cancer(BCLC)stage D ],79(66.4%) with Child-Pugh class C,78(65.5%) with pre-existing diseases,and 90(75.6%) with tumor metastasis among the 119 patients with HBV-PLC;The median overall survival in this series was 287(172,560) days,and the median overall survivals of patients with non-antiviral therapy,with antiviral therapy for less than one year,with antiviral therapy for one to three years,and with antiviral therapy for more than 3 years were 232(114,390) days,357(179,879) days,530 (206-)days,and 795(384,912) days (P<0.01);The Cox proportional-hazards model demonstrated that nationality [relative risk(RR)=3.18,95% CI,1.71~5.91,P=0.000],Child-Pugh class(RR=1.60,95%CI,1.180~2.16,P=0.002),tumor metastasis(RR=4.86,95%CI,2.72~8.68,P=0.000),age(RR=1.82,95%CI,1.13~2.95,P=0.014),antiviral therapy prior to diagnosis of HBV-PLC(RR=1.30,95%CI,1.00~1.69,P=0.048),serum HBV DNA level (RR=5.88,95%CI,3.22~10.71,P=0.000)and the way targeting tumor therapy (RR=1.13,95%CI,1.01~1.26,P=0.025) were significant predictor of overall survival. Conclusion Many factors might influence the overall survival of patients with HBV-PLC,and the rigorous screening and surveillance in the HBV-infected populations,and effective antiviral therapy for HBV infection are important for prolonging the life of patients with PLC.

Key words: Primary liver cancer, Hepatitis B, Risk factors, Survival